Products

Human BCAS4(Breast Carcinoma Amplified Sequence 4) ELISA Kit
ELK5397
Size： Price：
48 T $320.00
96 T $458.00
Download ① Send email to us

Overview

Product name: Human BCAS4(Breast Carcinoma Amplified Sequence 4) ELISA Kit
Reactivity: Human
Alternative Names: CNOL
Assay Type: Sandwich
Sensitivity: 0.055 ng/mL
Standard: 10 ng/mL
Detection Range: 0.16-10 ng/mL
Sample Type: tissue homogenates, cell lysates and other biological fluids
Assay Length: 3.5h
Research Area: Tumor immunity;
Uniprot ID: Q8TDM0
Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human BCAS4. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human BCAS4. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human BCAS4, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human BCAS4 in the samples is then determined by comparing the OD of the samples to the standard curve.

Standard curve

Concentration (ng/mL) OD Corrected OD
10.00 2.165 2.079
5.00 1.663 1.577
2.50 1.116 1.030
1.25 0.871 0.785
0.63 0.508 0.422
0.32 0.423 0.337
0.16 0.232 0.146
0.00 0.086 0.000

Precision

Intra-assay Precision (Precision within an assay)：CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays)：CV%<10%

Three samples of known concentration were tested in forty separate assays to assess inter-assay precision.

Recovery

Matrices listed below were spiked with certain level of recombinant BCAS4 and the recovery rates were calculated by comparing the measured value to the expected amount of BCAS4 in samples.
Matrix Recovery range Average
serum(n=5) 81-97% 89%
EDTA plasma(n=5) 84-97% 90%
Heparin plasma(n=5) 82-94% 88%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of BCAS4 and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Matrix 1:2 1:4 1:8 1:16
serum(n=5) 95-102% 97-105% 87-94% 93-101%
EDTA plasma(n=5) 86-101% 86-101% 87-96% 92-105%
Heparin plasma(n=5) 86-97% 88-95% 92-101% 87-98%